Trials / Completed
CompletedNCT00330330
Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment
A Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Activity of ISIS 113715 in Patients With Type 2 Diabetes Mellitus Who Have Not Received Prior Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 96 (planned)
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the safety, tolerability, and pharmacokinetics of five ISIS 113715 intravenous dose cohorts in drug-naïve type 2 diabetics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ISIS 113715 |
Timeline
- Start date
- 2003-02-01
- Completion
- 2006-08-01
- First posted
- 2006-05-26
- Last updated
- 2008-02-06
Locations
10 sites across 2 countries: Poland, Russia
Source: ClinicalTrials.gov record NCT00330330. Inclusion in this directory is not an endorsement.